Literature DB >> 19734414

Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drug.

Alan G Ramsay, John G Gribben.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19734414      PMCID： PMC2738710          DOI： 10.3324/haematol.2009.009274

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  19 in total

1.  T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy.

Authors:  Angela M Krackhardt; Sabine Harig; Mathias Witzens; Ryan Broderick; Patrick Barrett; John G Gribben
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

Review 2.  Immunomodulating drugs for chronic lymphocytic leukaemia.

Authors:  Asher Chanan-Khan; Carl W Porter
Journal:  Lancet Oncol       Date:  2006-06       Impact factor: 41.316

Review 3.  Regulation of T-cell activation by the cytoskeleton.

Authors:  Daniel D Billadeau; Jeffrey C Nolz; Timothy S Gomez
Journal:  Nat Rev Immunol       Date:  2007-02       Impact factor: 53.106

4.  Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

Authors:  Güllü Görgün; Tobias A W Holderried; David Zahrieh; Donna Neuberg; John G Gribben
Journal:  J Clin Invest       Date:  2005-06-16       Impact factor: 14.808

Review 5.  Cellular immune therapy for chronic lymphocytic leukemia.

Authors:  Arnon P Kater; Marinus H J van Oers; Thomas J Kipps
Journal:  Blood       Date:  2007-07-16       Impact factor: 22.113

6.  Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Authors:  Asher Chanan-Khan; Kena C Miller; Laurie Musial; David Lawrence; Swaminathan Padmanabhan; Kenichi Takeshita; Carl W Porter; David W Goodrich; Zale P Bernstein; Paul Wallace; David Spaner; Alice Mohr; Catriona Byrne; Francisco Hernandez-Ilizaliturri; Cynthia Chrystal; Petr Starostik; Myron S Czuczman
Journal:  J Clin Oncol       Date:  2006-11-06       Impact factor: 44.544

Review 7.  Lenalidomide for the treatment of B-cell malignancies.

Authors:  Asher A Chanan-Khan; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2008-02-19       Impact factor: 44.544

8.  Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.

Authors:  Leslie A Andritsos; Amy J Johnson; Gerard Lozanski; William Blum; Cheryl Kefauver; Farrukh Awan; Lisa L Smith; Rosa Lapalombella; Sarah E May; Chelsey A Raymond; Da-Sheng Wang; Robert D Knight; Amy S Ruppert; Amy Lehman; David Jarjoura; Ching-Shih Chen; John C Byrd
Journal:  J Clin Oncol       Date:  2008-04-21       Impact factor: 44.544

9.  Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; Bang-Ning Lee; Ellen J Schlette; Susan M O'Brien; Hui Gao; Sijin Wen; William G Wierda; Zeev Estrov; Stefan Faderl; Evan N Cohen; Changping Li; James M Reuben; Michael J Keating
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113

10.  Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.

Authors:  Georg Aue; Ndegwa Njuguna; Xin Tian; Susan Soto; Thomas Hughes; Berengere Vire; Keyvan Keyvanfar; Federica Gibellini; Janet Valdez; Carol Boss; Leigh Samsel; J Philip McCoy; Wyndham H Wilson; Stefania Pittaluga; Adrian Wiestner
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941
View more
  18 in total

Review 1.  Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.

Authors:  Philip A Thompson; William G Wierda
Journal:  Blood       Date:  2015-11-17       Impact factor: 22.113

2.  Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.

Authors:  Julie E Chang; Thomas Havighurst; KyungMann Kim; Jens Eickhoff; Anne M Traynor; Rachel Kirby-Slimp; Lynn M Volk; Jae Werndli; Ronald S Go; Matthias Weiss; Jules Blank; Brad S Kahl
Journal:  Br J Haematol       Date:  2016-02-23       Impact factor: 6.998

3.  Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia.

Authors:  Georg Aue; Jay Nelson Lozier; Xin Tian; Ann M Cullinane; Susan Soto; Leigh Samsel; Philip McCoy; Adrian Wiestner
Journal:  Am J Hematol       Date:  2011-08-02       Impact factor: 10.047

4.  Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.

Authors:  Asher A Chanan-Khan; Kasyapa Chitta; Noreen Ersing; Aneel Paulus; Aisha Masood; Taimur Sher; Abhisek Swaika; Paul K Wallace; Terry L Mashtare; Greg Wilding; Kelvin Lee; Myron S Czuczman; Ivan Borrello; Naveen Bangia
Journal:  Br J Haematol       Date:  2011-10-20       Impact factor: 6.998

5.  Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide.

Authors:  Alan G Ramsay; Rachel Evans; Shahryar Kiaii; Lena Svensson; Nancy Hogg; John G Gribben
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

Review 6.  Novel Therapy Approaches to Follicular Lymphoma.

Authors:  Michael Northend; William Townsend
Journal:  Drugs       Date:  2021-03       Impact factor: 9.546

Review 7.  Lenalidomide alone and in combination for chronic lymphocytic leukemia.

Authors:  Christine I Chen
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

8.  On the geometric modeling approach to empirical null distribution estimation for empirical Bayes modeling of multiple hypothesis testing.

Authors:  Baolin Wu
Journal:  Comput Biol Chem       Date:  2012-12-22       Impact factor: 2.877

9.  Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.

Authors:  Candida Vitale; Lorenzo Falchi; Elisa Ten Hacken; Hui Gao; Hila Shaim; Katrien Van Roosbroeck; George Calin; Susan O'Brien; Stefan Faderl; Xuemei Wang; William G Wierda; Katayoun Rezvani; James M Reuben; Jan A Burger; Michael J Keating; Alessandra Ferrajoli
Journal:  Clin Cancer Res       Date:  2016-01-05       Impact factor: 12.531

10.  Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.

Authors:  David L Porter; Wei-Ting Hwang; Noelle V Frey; Simon F Lacey; Pamela A Shaw; Alison W Loren; Adam Bagg; Katherine T Marcucci; Angela Shen; Vanessa Gonzalez; David Ambrose; Stephan A Grupp; Anne Chew; Zhaohui Zheng; Michael C Milone; Bruce L Levine; Jan J Melenhorst; Carl H June
Journal:  Sci Transl Med       Date:  2015-09-02       Impact factor: 17.956
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.